With R&D flops mounting, Eli Lilly likely to slash budget, analysts say

Tracy Staton The litany of clinical trial failures for Eli Lilly's pipeline programs is likely to force the company to start carving up its R&D budget as the pharma giant enters ...

Former Lilly scientists indicted for passing R&D secrets to Chinese drugmaker

Tracy Staton Two former Eli Lilly scientists stand accused of passing laboratory trade secrets to a Chinese drugmaker. Guoqing Cao and Shuyu "Dan" Li are held without bail ...

Lilly warns of ‘challenging’ bid for 2014 sales goal, thanks to yen, emerging markets

Tracy Staton Meeting next year's minimum revenue goal of $ 20 billion will be "challenging," Eli Lilly says, and analysts are already speculating about "savage" ...

Lilly fails to persuade Medicare to pay for Alzheimer’s imaging drug

Tracy Staton The Centers for Medicare & Medicaid Services has handed down its final decision on Eli Lilly's Alzheimer's imaging agent Amyvid. The final answer, after appeals ...

Lilly Announces Positive Type 2 Diabetes Data

mia.burns Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly’s Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes Improvements ...

Eli Lilly plans low-cost launch strategy for new diabetes drugs

John Carroll As Lilly Diabetes President Enrique Conterno tells Bloomberg, the company plans to lean on its broad product portfolio to grow sales, rather than sending out legions of ...

Lilly files $500M lawsuit against Canada

Eric Palmer Eli Lilly has ratcheted up its international fight with Canada over what it considers unfair patent rulings. The Indianapolis, IN-based Lilly has now filed a $ 500 million ...

A $500 Million Brawl: Lilly, Canada And Invalidated Patents

esilverman In the latest twist in the brawl between Eli Lilly and the Canadian government over invalidated patents, the drugmaker has filed for arbitration and is seeking nearly ...

With NIH support, Eli Lilly follows NPS Pharma into hunt for rare-disease therapy

Ryan McBride Eli Lilly has found a new path into the hot rare-disease field. An NIH program has backed the Indianapolis-based drug giant's preclinical-stage research of a potential ...

Eli Lilly expects no clarity on Alimta monopoly till 2014

Tracy Staton Eli Lilly's fight to extend Alimta exclusivity will drag into next year. As Reuters reports, a patent trial may have wrapped up last week, but both sides ...

Eli Lilly inks $200M armed antibody pact with ImmunoGen

John Carroll ImmunoGen says it's struck a $ 200 million deal to collaborate with Eli Lilly ($ LLY) on developing new armed antibodies. FierceBiotech News

Lilly, Humana in Research Pact

barbara.lempert Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes Companies embark on evidence-based research effort to advance health care outcomes LOUISVILLE, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS